Location of EGFR exon 20 insertions matters

Cancer Cell. 2022 Jul 11;40(7):705-708. doi: 10.1016/j.ccell.2022.06.002.

Abstract

EGFR exon 20 insertions represent a subgroup of NSCLC patients posed with a therapy dilemma. In this issue of Cancer Cell, Elamin and colleagues demonstrate that only insertions localized in the near loop respond to poziotinib. Pharmacological inhibition of spindle assembly checkpoint components inhibits tumor growth in poziotinib-resistant exon 20 insertions.

Publication types

  • Comment

MeSH terms

  • ErbB Receptors* / genetics
  • Exons / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Protein Kinase Inhibitors
  • EGFR protein, human
  • ErbB Receptors